Trinity Biotech (TRIB) vs VolitionRX (VNRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
VolitionRX is the larger company by market cap ($6.6 million vs $4.9 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | TRIB | VNRX |
|---|---|---|
| Share price | $6.04 | $0.2194 |
| Market cap | $4.91M | $6.60M |
| 1-day change | -10.91% | -2.92% |
| EPS (TTM) | $-60.00 | $-3.80 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $52.50 | $12.80 |
| 52-week low | $5.01 | $0.217 |
| Distance from 52-week high | -88.50% | -98.29% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +6107.84% |
| Average volume | 21.63K | 8.46M |
| Shares outstanding | 813.13K | 30.06M |
| Employees | 287 | 57 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Trinity Biotech
TRIB stock →Trinity Biotech plc, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases, such as syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic measurement of haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
Healthcare · Medical Devices · 287 employees
About VolitionRX
VNRX stock →VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes.
Healthcare · Medical Devices · 57 employees
TRIB vs VNRX FAQ
Which is bigger, Trinity Biotech or VolitionRX?
VolitionRX (VNRX) is larger, with a market capitalization of $6.60M compared with $4.91M for Trinity Biotech (TRIB).
Are Trinity Biotech and VolitionRX in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.